Perrigo Company plc is a leading global healthcare company based in Ireland. The company specializes in the production and distribution of over-the-counter (OTC) pharmaceutical products and generic medications. Perrigo's headquarters are located in Dublin, Ireland.

The history of Perrigo dates back to 1887 when a small general store was established in Michigan, USA. Over the years, the company evolved into a pharmaceutical company, manufacturing its own products and acquiring several businesses to expand its portfolio. In 2013, Perrigo completed the acquisition of Elan Corporation, a biotechnology company, and became Perrigo Company plc with its headquarters in Ireland.

Perrigo offers a wide range of products and services across various healthcare sectors. Its main products include OTC medications, generic prescription drugs, infant formula, vitamins and supplements, and animal health products. The company's extensive product portfolio enables them to cater to a diverse customer base worldwide.

With operations on a global scale, Perrigo operates in multiple markets and has a strong presence in North America, Europe, and other regions. The company has numerous subsidiaries, including Perrigo Australia, Perrigo Israel Pharmaceuticals, and Perrigo UK. Perrigo also has joint ventures and partnerships to expand its reach and diversify its product offerings.

In terms of market position, Perrigo is one of the largest OTC pharmaceutical companies globally. The company has grown significantly through acquisitions and strategic partnerships, establishing itself as a formidable competitor in the industry. Perrigo has a strong distribution network and maintains relationships with major retailers and pharmacies worldwide.

Throughout its history, Perrigo has experienced several major events and achievements. One notable achievement was the acquisition of Omega Pharma in 2015, which significantly expanded Perrigo's presence in Europe. The company also made strategic divestments to focus on its core business areas and strengthen its financial position.

Currently, Perrigo continues to strengthen its market position through innovation and partnerships. The company emphasizes research and development, aiming to introduce new products and technologies to meet customer needs. Perrigo's commitment to quality and affordability has played a significant role in its steady growth and success.

As of the latest available information, Perrigo Company plc continues to be a leading global healthcare company with a strong market presence. The company's dedication to global expansion, innovative product development, and strategic partnerships positions it well for future growth and success